Enlivex Therapeutics’ (ENLV) “Buy” Rating Reaffirmed at D. Boral Capital

Enlivex Therapeutics (NASDAQ:ENLV)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $13.00 price objective on the stock.

ENLV has been the topic of several other research reports. EF Hutton Acquisition Co. I upgraded Enlivex Therapeutics to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Enlivex Therapeutics in a research note on Friday, September 27th.

Enlivex Therapeutics Stock Down 5.3 %

Shares of ENLV stock traded down $0.06 on Tuesday, hitting $1.08. The company had a trading volume of 81,455 shares, compared to its average volume of 180,095. Enlivex Therapeutics has a twelve month low of $0.81 and a twelve month high of $4.59. The company has a 50-day moving average price of $1.36 and a 200-day moving average price of $1.36. The firm has a market cap of $23.12 million, a P/E ratio of -0.92 and a beta of 1.01.

Enlivex Therapeutics (NASDAQ:ENLV) last released its earnings results on Friday, August 30th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.06. Equities research analysts expect that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENLV. XTX Topco Ltd bought a new stake in shares of Enlivex Therapeutics in the 2nd quarter worth about $35,000. Sigma Investment Counselors Inc. purchased a new stake in shares of Enlivex Therapeutics during the third quarter worth $50,000. Finally, Armistice Capital LLC acquired a new stake in shares of Enlivex Therapeutics during the second quarter worth about $2,415,000. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.